aaRSs are currently prioritized as targets for tuberculosis treatment as M. tuberculosis aaRS genes are vulnerable to knockdown (29) and a LeuRS/MetRS dual inhibitor is currently undergoing clinical trials (37). This evidence concerns the gene AARS1 and tuberculosis.